NTX-1955
NTX-1955, also known as RO-7308480, is a selective γ 1 subunit-containing GABA A receptor positive allosteric modulator which is under development for the treatment of generalized anxiety disorder.
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NTX-1955, also known as RO-7308480, is a selective γ 1 subunit-containing GABA A receptor positive allosteric modulator which is under development for the treatment of generalized anxiety disorder. It is taken orally. Classical benzodiazepines are GABA A receptor positive allosteric modulators that act mainly upon γ 2 subunit-containing GABA A receptors.
GABA A receptor γ 2 subunits are the most abundantly expressed GABA A receptor subunits in the brain and are present in at least 90% of all GABA A receptors in the forebrain. Moreover, they show high expression in the amygdala and have been extensively implicated in suppressing anxiety via actions in this area.
Conversely, NTX-1955 is a selective positive allosteric modulator of γ 1 subunit-containing GABA A receptors. Though γ 2 subunit-containing GABA A receptors are dominant in this area, γ 1 subunit-containing GABA A receptors are also highly expressed in the central amygdala, and selective positive allosteric modulators of these receptors have been found to produce anxiolytic-like effects without side effects like sedation and cognitive and motor impairment in animals.
As such, it is thought that selectivity for γ 1 subunit-containing GABA A receptors may confer improved tolerability compared to existing drugs like benzodiazepines. Due to its novel mechanism of action, NTX-1955 is a potential first-in-class medication.…
NTX-1955, also known as RO-7308480, is a selective γ 1 subunit-containing GABA A receptor positive allosteric modulator which is under development for the treatment of generalized anxiety disorder. It is taken orally. Classical benzodiazepines are GABA A receptor positive allosteric modulators that act mainly upon γ 2 subunit-containing GABA A receptors.
GABA A receptor γ 2 subunits are the most abundantly expressed GABA A receptor subunits in the brain and are present in at least 90% of all GABA A receptors in the forebrain. Moreover, they show high expression in the amygdala and have been extensively implicated in suppressing anxiety via actions in this area.
Conversely, NTX-1955 is a selective positive allosteric modulator of γ 1 subunit-containing GABA A receptors. Though γ 2 subunit-containing GABA A receptors are dominant in this area, γ 1 subunit-containing GABA A receptors are also highly expressed in the central amygdala, and selective positive allosteric modulators of these receptors have been found to produce anxiolytic-like effects without side effects like sedation and cognitive and motor impairment in animals.
As such, it is thought that selectivity for γ 1 subunit-containing GABA A receptors may confer improved tolerability compared to existing drugs like benzodiazepines. Due to its novel mechanism of action, NTX-1955 is a potential first-in-class medication. NTX-1955 was originated by Roche and is under development by Newleos Therapeutics.
As of April 2026, it is in phase 1 clinical trials for generalized anxiety disorder, with several phase 1 trials having been completed. There was also interest in NTX-1955 for potential treatment of social anxiety disorder. The chemical structure of NTX-1955 does not yet appear to have been disclosed, but it is said to be structurally related to benzodiazepines.
See also
List of investigational generalized anxiety disorder drugs ENX-102 (TPA-023B)
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370412280 under CC BY-SA 4.0; modifications have been made.